Company
ASX:AVR
Anteris Technologies Pty Ltd is a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
133 stories · page 7 of 7
Data from its first-in-human trial will be presented at the conference to be held on November 22-24, 2020, virtually, given the COVID-19 restrictions.
The company is focused on developing next-generation technologies that help healthcare professionals create life-changing outcomes for patients.
Proven benefits of the ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to challen
Early results show that the DurAVR™ valve was easy to manipulate and able to be optimally positioned by the implanting surgeon in the aortic valve replacement procedures.
Business restrictions caused by COVID-19 precludes face-face meetings but this has not dampened interest in Anteris’ unique technology.
If these results continue, DurAVR™ will be the first TAVR valve to deliver a truly functional cure for severe aortic stenosis patients.
The company presented the data at the TAVR Key Opinion Leader Symposium held on July 20.
The structural heart company will update on its TAVR R&D program and the ongoing first-in-human trial of its ADAPT® 3D single-piece aortic valve for Surgical Aortic Valve Replacement procedures.
The company is focused on reaching its operational goals for 2020 including completing a study of its proprietary DurAVR™ Transcatheter Heart Valve by year-end.
The company’s DurAVR™ product is a highly durable 3D single-piece aortic valve for the treatment of aortic stenosis.
The company has received a tax incentive for R&D costs incurred in developing its ADAPT® technology and products including the DurAVR™ 3D single-piece Aortic Valve.
The study will allow the company to make refinements to the DurAVR™ aortic valve, which will be applied to the device used in the planned US FDA submission for a human clinical trial in 2021.
Anteris is a structural heart company with technology, ADAPT® and DurAVR™, that solves critical issues with marketed heart valves.
